| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 预测尿液pH的方法 | CN200680033306.0 | 2006-07-12 | CN101263387A | 2008-09-10 | R·M·亚姆卡 |
| 本发明提供了如下预测动物尿液pH的方法：测定动物摄取的食物中所选阳离子、阴离子和含硫氨基酸的量并使用将这些阳离子、阴离子和含硫氨基酸的量换算成尿液pH的公式预测尿液pH。通常，在动物摄取食物时，使用食物中阳离子钠、钾、钙和镁；阴离子氯离子、硫和磷；含硫氨基酸蛋氨酸和胱氨酸中所有或其子集的量预测动物尿液pH。 | ||||||
| 2 | 一种同时检测尿液中膀胱癌细胞、结石、血细胞和细菌的微流控芯片 | CN201510263042.9 | 2015-05-21 | CN104965082A | 2015-10-07 | 刘波; 李驰宇; 李旺; 耿春阳; 辛嘉龙 |
| 本发明属于细胞检测装置技术领域，涉及一种同时检测尿液中膀胱癌细胞、结石、血细胞和细菌的微流控芯片。其下层的样品通道层和上层控制样品通道开关的气动微阀层；下层的样品通道层由尿液样本入口、尿液样品主通道、尿液样本出口储液池组成，尿液样品主通道上各检测单元；检测单元包括尿液结石拦截单元、膀胱移行上皮癌细胞检测单元、膀胱腺癌细胞检测单元、膀胱鳞癌细胞检测单元、血细胞检测单元和细菌检测单元，各检测单元串联且呈圆对称分布。本发明的芯片具有高特异性，高灵敏性，可以实现仅仅检测尿液就可以判断是否患有膀胱癌和尿路症状，是一种廉价高效的尿液检测工具。 | ||||||
| 3 | 一种多通道进样的泌尿系结石病因诊断系统及应用方法 | CN201310195206.X | 2013-05-22 | CN103308611A | 2013-09-18 | 刘冠琳; 阎亮; 程跃; 傅豪刚; 杨文森 |
| 本发明涉及一种多通道自动进样的泌尿系结石病因诊断系统及其应用方法，包括生化分析仪、电子病历系统、多通道液相色谱仪装置和数码显微摄影装置，还包括中央处理计算机，生化分析仪、电子病历系统、多通道液相色谱仪装置和数码显微摄影装置分别连接中央处理计算机，多通道液相色谱仪装置包括两个以上的液相色谱仪和自动进样器，自动进样器连接液相色谱仪。本诊断系统在国内外首次将病因诊断繁琐的工作流程规范化和简单化，将繁琐的检测和诊断的过程整理形成自动化。 | ||||||
| 4 | 一种多通道进样的泌尿系结石病因诊断系统及应用方法 | CN201310195206.X | 2013-05-22 | CN103308611B | 2017-02-22 | 刘冠琳; 阎亮; 程跃; 傅豪刚; 杨文森 |
| 本发明涉及一种多通道自动进样的泌尿系结石病因诊断系统及其应用方法，包括生化分析仪、电子病历系统、多通道液相色谱仪装置和数码显微摄影装置，还包括中央处理计算机，生化分析仪、电子病历系统、多通道液相色谱仪装置和数码显微摄影装置分别连接中央处理计算机，多通道液相色谱仪装置包括两个以上的液相色谱仪和自动进样器，自动进样器连接液相色谱仪。本诊断系统在国内外首次将病因诊断繁琐的工作流程规范化和简单化，将繁琐的检测和诊断的过程整理形成自动化。 | ||||||
| 5 | 预测尿液pH的方法 | CN200680033306.0 | 2006-07-12 | CN101263387B | 2014-08-13 | R·M·亚姆卡 |
| 本发明提供了如下预测动物尿液pH的方法：测定动物摄取的食物中所选阳离子、阴离子和含硫氨基酸的量并使用将这些阳离子、阴离子和含硫氨基酸的量换算成尿液pH的公式预测尿液pH。通常，在动物摄取食物时，使用食物中阳离子钠、钾、钙和镁；阴离子氯离子、硫和磷；含硫氨基酸蛋氨酸和胱氨酸中所有或其子集的量预测动物尿液pH。 | ||||||
| 6 | Methods and devices for diagnosis of particles in biological fluids | US14897432 | 2014-06-11 | US10059978B2 | 2018-08-28 | Ozan Akkus; Mikhail Slipchenko; Anna Akkus; Shan Yang; Bolan Li |
| Methods for determining whether certain compounds, in particular crystals, are present in a sample of a biological fluid that indicates an individual has a particular disease or condition, such as but not limited to gout, pseudogout or urinary tract stones. In some embodiments, the methods include the steps of digestion and filtration of a sample of synovial fluid in order to isolate, if present, monosodium urate monohydrate (MSU), calcium pyrophosphate dihydrate (CPPD), or calcium phosphate crystals from the sample, wherein the filtrate is analyzed with a Raman device to ascertain the presence and type of the crystals. Devices for performing steps of the method are disclosed. | ||||||
| 7 | Peptide inhibitors of calcium oxalate monohydrate crystallization and uses thereof | US14326908 | 2014-07-09 | US09617306B2 | 2017-04-11 | Jeffrey D. Rimer; Pankaj Karande |
| In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides. Such a method may comprise designing a peptide library of potential calcium oxalate inhibiting peptides; screening the peptide library for high efficacy inhibitor peptides for inhibition of calcium oxalate monohydrate crystallization; and conducting molecular characterization of the high efficacy inhibitor to determine specificity. | ||||||
| 8 | Methods for Predicting Urine Ph | US11995577 | 2006-07-12 | US20090130222A1 | 2009-05-21 | Ryan Michael Yamka |
| The invention provides methods for predicting urine pH for an animal by determining the amount of selected cations, anions, and sulfur-containing amino acids in a food for consumption by the animal and predicting urine pH using a formula that equates the amount of such cations, anions, and sulfur-containing amino acids to urine pH. Generally, the amounts of all or a subset of the cations sodium, potassium, calcium, and magnesium; the anions are chloride, sulfur, and phosphorus; and the sulfur-containing amino acids methionine and cystine in a food are used to predict animal urine pH when the food is consumed by the animal. | ||||||
| 9 | METHODS OF DETERMINING URINARY CALCULI COMPOSITION | US15871750 | 2018-01-15 | US20180203001A1 | 2018-07-19 | Hon Sing LEONG; Andre ST. AMANT |
| A method of detecting urinary calculi in a subject. Detecting urinary calculi includes first exposing the urine sample to at least one labeled binding probe that is specific to calcium/magnesium-based urinary calculi and second detecting urinary calculi bound to the at least one labeled binding probe. Methods for measuring, monitoring and/or determining subtype of urinary stone composition in a subject are also provided. | ||||||
| 10 | METHODS AND DEVICES FOR DIAGNOSIS OF PARTICLES IN BIOLOGICAL FLUIDS | US14897432 | 2014-06-11 | US20160130632A1 | 2016-05-12 | Ozan Akkus; Mikhail Slipchenko; Anna Akkus; Shan Yang; Bolan Li |
| Methods for determining whether certain compounds, in particular crystals, are present in a sample of a biological fluid that indicates an individual has a particular disease or condition, such as but not limited to gout, pseudogout or urinary tract stones. In some embodiments, the methods include the steps of digestion and filtration of a sample of synovial fluid in order to isolate, if present, monosodium urate monohydrate (MSU), calcium pyrophosphate dihydrate (CPPD), or calcium phosphate crystals from the sample, wherein the filtrate is analyzed with a Raman device to ascertain the presence and type of the crystals. Devices for performing steps of the method are disclosed. | ||||||
| 11 | Biomarkers for renal disease | US12504429 | 2009-07-16 | US08394639B2 | 2013-03-12 | Hassan Dihazi; Gerhard A. Müller; Frank Strutz |
| The invention provides methods and kits for diagnosing a renal disease in a patient or for predicting the risk of a patient for developing a renal disease. In one embodiment, the invention provides a method for diagnosing a renal disease in a patient, comprising determining the level of a ubiquitin fragment having a mass-to-charge ratio (m/z) of 6188 (ubiquitin m/z 6188), or the level of a nucleic acid encoding ubiquitin m/z 6188, in a sample derived from said patient, wherein the substantial absence or a reduced level of less than 25% of ubiquitin m/z 6188 or the nucleic acid encoding ubiquitin m/z 6188 compared to a control is indicative of the renal disease in said patient. | ||||||
| 12 | BIOMARKERS FOR RENAL DISEASE | US12504429 | 2009-07-16 | US20100035263A1 | 2010-02-11 | Hassan DIHAZI; Gerhard A. Müller; Frank Strutz |
| The invention provides methods and kits for diagnosing a renal disease in a patient or for predicting the risk of a patient for developing a renal disease. In one embodiment, the invention provides a method for diagnosing a renal disease in a patient, comprising determining the level of a ubiquitin fragment having a mass-to-charge ratio (m/z) of 6188 (ubiquitin m/z 6188), or the level of a nucleic acid encoding ubiquitin m/z 6188, in a sample derived from said patient, wherein the substantial absence or a reduced level of less than 25% of ubiquitin m/z 6188 or the nucleic acid encoding ubiquitin m/z 6188 compared to a control is indicative of the renal disease in said patient. | ||||||
| 13 | Assessing risk for kidney stones using parathyroid hormone agonist and antagonist | US11144437 | 2005-06-03 | US07541140B2 | 2009-06-02 | Thomas L. Cantor |
| The present invention relates to identifying the risk of a subject developing renal stones utilizing an assessment of PTH agonist, antagonist and/or total PTH levels, optionally together with an assessment of serum and/or urine calcium levels and/or other analytes. The present description further relates to monitoring and guiding treatment for renal stones and kits useful therefore. | ||||||
| 14 | Assessing risk for kidney stones | US11144437 | 2005-06-03 | US20060035282A1 | 2006-02-16 | Thomas Cantor |
| The present invention relates to identifying the risk of a subject developing renal stones utilizing an assessment of PTH agonist, antagonist and/or total PTH levels, optionally together with an assessment of serum and/or urine calcium levels and/or other analytes. The present description further relates to monitoring and guiding treatment for renal stones and kits useful therefore. | ||||||
| 15 | Method for predicting urine pH | JP2008521518 | 2006-07-12 | JP4966303B2 | 2012-07-04 | ヤムカ，ライアン・マイケル |
| 16 | Method for predicting urine pH | JP2008521518 | 2006-07-12 | JP2009501342A | 2009-01-15 | ヤムカ，ライアン・マイケル |
| 本発明は、動物の尿ｐＨを予測する方法であって、動物による消費用食品中の選択された陽イオン、陰イオン、および硫黄含有アミノ酸の量を決定し、そしてこのような陽イオン、陰イオン、および硫黄含有アミノ酸の量を尿ｐＨへと等式化する式を用いて尿ｐＨを予測することによる方法を提供する。 概して、食品中の陽イオンであるナトリウム、カリウム、カルシウムおよびマグネシウム；塩化物、硫黄およびリンである陰イオン；および硫黄含有アミノ酸であるメチオニンおよびシスチンの全部または部分集合の量を用いて、その食品が動物によって消費された場合の動物の尿ｐＨを予測する。 | ||||||
| 17 | PEPTIDE INHIBITORS OF CALCIUM OXALATE MONOHYDRATE CRYSTALLIZATION AND USES THEREOF | US15446253 | 2017-03-01 | US20170283459A1 | 2017-10-05 | Jeffrey D. Rimer; Pankaj Karande |
| In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides. Such a method may comprise designing a peptide library of potential calcium oxalate inhibiting peptides; screening the peptide library for high efficacy inhibitor peptides for inhibition of calcium oxalate monohydrate crystallization; and conducting molecular characterization of the high efficacy inhibitor to determine specificity. | ||||||
| 18 | Urinary Crystal Detection System and Method Thereof | US14455395 | 2014-08-08 | US20150204880A1 | 2015-07-23 | Hui-Hua Chiang; Yi-Chun Chiu; Chih-Chia Huang |
| The present invention provides an urinary crystal detection system, which comprises a crystal collecting unit and a crystal detecting unit, wherein the crystal collecting unit comprises a magnetic separating device. Further, the present invention provides an urinary crystal detection method, which uses magnetic particles to adsorb onto urinary crystals, then, provides a magnetic field to separate the urinary crystals and detect their constituent by the Raman signals of the urinary crystal. | ||||||
| 19 | Peptide Inhibitors of Calcium Oxalate Monohydrate Crystallization and Uses Thereof | US14326908 | 2014-07-09 | US20150099704A1 | 2015-04-09 | Jeffrey D. Rimer; Pankaj Karande |
| In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides. Such a method may comprise designing a peptide library of potential calcium oxalate inhibiting peptides; screening the peptide library for high efficacy inhibitor peptides for inhibition of calcium oxalate monohydrate crystallization; and conducting molecular characterization of the high efficacy inhibitor to determine specificity. | ||||||
| 20 | Diagnosis and treatment of kidney stones, methods and compositions therefor | US14191356 | 2014-02-26 | US20140242609A1 | 2014-08-28 | Jianghui Hou; Yongfeng Gong |
| Methods of detecting, diagnosing, monitoring and treating kidney stones are disclosed. In some embodiments, methods of detecting, diagnosing or monitoring kidney stones comprise contacting a urine sample with anti-Claudin-14 antibody, and detecting quantity of a complex comprising Claudin-14 and the antibody, wherein an increase compared to control levels is diagnostic for kidney stones. In some embodiments, methods further comprise testing a second sample at a second time point to detect increased kidney stones. In some embodiments, methods of treating kidney stone disease comprise administering an miR-9 mimic or an miR-374 mimic. In some embodiments, methods comprise administering an inhibitor of CaSR signaling. In some embodiments, methods comprise administering a HDAC inhibitor. In some embodiments methods of treating hyperparathyroidism and hypercalcemia are disclosed, comprising administering an agonist of CaSR. Methods of abrogating CaSR-mediated regulation of claudin-14, microRNAs and urinary Ca++ excretion are disclosed, comprising administering a calcineurin inhibitor. | ||||||
QQ群二维码
意见反馈
意见反馈